Clinical Trials Logo

Hypersensitivity Reaction clinical trials

View clinical trials related to Hypersensitivity Reaction.

Filter by:
  • None
  • Page 1

NCT ID: NCT04035707 Completed - Clinical trials for Hypersensitivity Reaction

Serum Tryptase Concentration During General Anaesthesia With Rocuronium

Start date: June 25, 2009
Phase: N/A
Study type: Interventional

Rocuronium is a aminosteroid structured, non-depolarizing neuromuscular blocking agents (NMB). Epidemiological data presents that the frequency of hypersensitivity reactions caused by rocuronium have been increased. Determinations of serum tryptase concentrations are interdisciplinary recommended in diagnosis of its adverse reactions. No studies have been performed to explain specific role of rocuronium doses on serum tryptase values. The aim of this study was to investigate the potential effect of rocuronium on serum tryptase concentrations.

NCT ID: NCT02349763 Completed - Clinical trials for Hypersensitivity Reaction

Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction

DEPARO
Start date: February 28, 2015
Phase: Phase 3
Study type: Interventional

Comparison of the efficacy and side effects of intravenous and oral regimens of dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reactions in primary ovarian, fallopian tube and peritoneal cancer patients receiving first cycle of combination paclitaxel and carboplatin.

NCT ID: NCT02185651 Terminated - Pompe Disease Clinical Trials

A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction

Start date: October 2016
Phase: Phase 1
Study type: Interventional

Hypothesis: the effectiveness of treatment of Pompe disease with rhGAA enzyme replacement therapy (ERT) is limited at least in part because patients develop antibodies against the provided rhGAA enzyme. Treatment with Zavesca® prior to infusion may dampen or eliminate the anti-rhGAA immune response in patients receiving ERT, thereby allowing for greater ERT efficacy. Treatment with Zavesca® before a enzyme replacement therapy (ERT) may decrease the severity of, or eliminate infusion associated reactions (IAR) in people with Pompe Disease receiving ERT.